Cargando…

Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits

BACKGROUND: Recent studies suggest that circulating endothelial progenitor cells (EPCs) may influence the response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the effect of CRT on EPC levels and to assess the impact of EPCs on long-term clinical outcomes. POPULA...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristóvão, Gonçalo, Milner, James, Sousa, Pedro, Ventura, Miguel, Cristóvão, João, Elvas, Luís, Paiva, Artur, Gonçalves, Lino, Ribeiro, Carlos Fontes, António, Natália
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245793/
https://www.ncbi.nlm.nih.gov/pubmed/32448383
http://dx.doi.org/10.1186/s13287-020-01713-8
_version_ 1783537818296909824
author Cristóvão, Gonçalo
Milner, James
Sousa, Pedro
Ventura, Miguel
Cristóvão, João
Elvas, Luís
Paiva, Artur
Gonçalves, Lino
Ribeiro, Carlos Fontes
António, Natália
author_facet Cristóvão, Gonçalo
Milner, James
Sousa, Pedro
Ventura, Miguel
Cristóvão, João
Elvas, Luís
Paiva, Artur
Gonçalves, Lino
Ribeiro, Carlos Fontes
António, Natália
author_sort Cristóvão, Gonçalo
collection PubMed
description BACKGROUND: Recent studies suggest that circulating endothelial progenitor cells (EPCs) may influence the response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the effect of CRT on EPC levels and to assess the impact of EPCs on long-term clinical outcomes. POPULATION AND METHODS: Prospective study of 50 patients submitted to CRT. Two populations of circulating EPCs were quantified previously to CRT implantation: CD34(+)KDR(+) and CD133(+)KDR(+) cells. EPC levels were reassessed 6 months after CRT. Endpoints during the long-term follow-up were all-cause mortality, heart transplantation, and hospitalization for heart failure (HF) management. RESULTS: The proportion of non-responders to CRT was 42% and tended to be higher in patients with an ischemic vs non-ischemic etiology (64% vs 35%, p = 0.098). Patients with ischemic cardiomyopathy (ICM) showed significantly lower CD34(+)KDR(+) EPC levels when compared to non-ischemic dilated cardiomyopathy patients (DCM) (0.0010 ± 0.0007 vs 0.0030 ± 0.0024 cells/100 leukocytes, p = 0.032). There were no significant differences in baseline EPC levels between survivors and non-survivors nor between patients who were rehospitalized for HF management during follow-up or not. At 6-month follow-up, circulating EPC levels were significantly higher than baseline levels (0.0024 ± 0.0023 vs 0.0047 ± 0.0041 CD34(+)KDR(+) cells/100 leukocytes, p = 0.010 and 0.0007 ± 0.0004 vs 0.0016 vs 0.0013 CD133(+)/KDR(+) cells/100 leukocytes, p = 0.007). CONCLUSIONS: Patients with ICM showed significantly lower levels of circulating EPCs when compared to their counterparts. CRT seems to improve the pool of endogenously circulating EPCs and reduced baseline EPC levels seem not to influence long-term outcomes after CRT. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7245793
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72457932020-06-01 Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits Cristóvão, Gonçalo Milner, James Sousa, Pedro Ventura, Miguel Cristóvão, João Elvas, Luís Paiva, Artur Gonçalves, Lino Ribeiro, Carlos Fontes António, Natália Stem Cell Res Ther Research BACKGROUND: Recent studies suggest that circulating endothelial progenitor cells (EPCs) may influence the response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the effect of CRT on EPC levels and to assess the impact of EPCs on long-term clinical outcomes. POPULATION AND METHODS: Prospective study of 50 patients submitted to CRT. Two populations of circulating EPCs were quantified previously to CRT implantation: CD34(+)KDR(+) and CD133(+)KDR(+) cells. EPC levels were reassessed 6 months after CRT. Endpoints during the long-term follow-up were all-cause mortality, heart transplantation, and hospitalization for heart failure (HF) management. RESULTS: The proportion of non-responders to CRT was 42% and tended to be higher in patients with an ischemic vs non-ischemic etiology (64% vs 35%, p = 0.098). Patients with ischemic cardiomyopathy (ICM) showed significantly lower CD34(+)KDR(+) EPC levels when compared to non-ischemic dilated cardiomyopathy patients (DCM) (0.0010 ± 0.0007 vs 0.0030 ± 0.0024 cells/100 leukocytes, p = 0.032). There were no significant differences in baseline EPC levels between survivors and non-survivors nor between patients who were rehospitalized for HF management during follow-up or not. At 6-month follow-up, circulating EPC levels were significantly higher than baseline levels (0.0024 ± 0.0023 vs 0.0047 ± 0.0041 CD34(+)KDR(+) cells/100 leukocytes, p = 0.010 and 0.0007 ± 0.0004 vs 0.0016 vs 0.0013 CD133(+)/KDR(+) cells/100 leukocytes, p = 0.007). CONCLUSIONS: Patients with ICM showed significantly lower levels of circulating EPCs when compared to their counterparts. CRT seems to improve the pool of endogenously circulating EPCs and reduced baseline EPC levels seem not to influence long-term outcomes after CRT. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-05-24 /pmc/articles/PMC7245793/ /pubmed/32448383 http://dx.doi.org/10.1186/s13287-020-01713-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cristóvão, Gonçalo
Milner, James
Sousa, Pedro
Ventura, Miguel
Cristóvão, João
Elvas, Luís
Paiva, Artur
Gonçalves, Lino
Ribeiro, Carlos Fontes
António, Natália
Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title_full Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title_fullStr Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title_full_unstemmed Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title_short Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
title_sort improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245793/
https://www.ncbi.nlm.nih.gov/pubmed/32448383
http://dx.doi.org/10.1186/s13287-020-01713-8
work_keys_str_mv AT cristovaogoncalo improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT milnerjames improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT sousapedro improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT venturamiguel improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT cristovaojoao improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT elvasluis improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT paivaartur improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT goncalveslino improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT ribeirocarlosfontes improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits
AT antonionatalia improvementincirculatingendothelialprogenitorcellspoolaftercardiacresynchronizationtherapyincreasingthelistofbenefits